###
中国临床研究英文版:2020,33(4):528-530,535
本文二维码信息
码上扫一扫!
金水宝联合含环丝氨酸化疗方案对耐多药肺结核患者免疫功能的调节
(1.广西龙潭医院结核3病区,广西 柳州545005;2.广西医科大学第四附属医院 柳州市工人医院内分泌科,广西 柳州545005)
Regulation of Jinshuibao combined with chemotherapy regimen containing cycloserine on immune function in MDR-TB patients
摘要
本文已被:浏览 673次   下载 421
Received:August 21, 2019   Published Online:April 20, 2020
中文摘要: 目的 探讨金水宝胶囊联合含环丝氨酸化疗方案对耐多药肺结核患者免疫功能的调节作用。 方法 将2015年1月至2016年1月收治的80例耐多药肺结核患者,按随机数字表法分为观察组和对照组,每组40例。对照组采用含环丝氨酸化疗方案治疗,即 6Am-Z-Lfx-Cs-Pto/18Z-Lfx-Cs-Pto[阿米卡星(Am)-吡嗪酰胺(Z)-左氧氟沙星(Lfx)-环丝氨酸(Cs)-丙硫异烟胺(Pto)]。 观察组在对照组基础上,采用金水宝胶囊治疗。比较两组的中医疗效、空洞疗效、病灶疗效。检测患者治疗前后T淋巴细胞亚群(CD3+、CD4+、CD8+、CD4+/CD8+)和自然杀伤(NK)细胞的水平。观察和记录两组患者在治疗过程中不良反应的发生情况。 结果 两组的中医疗效、空洞疗效、病灶疗效对比,差异无统计学意义(P均>0.05)。观察组治疗后的CD3+、CD4+、CD4+/CD8+、NK细胞明显升高,且高于对照组治疗后;CD8+明显降低,且低于对照组治疗后,差异有统计学意义(P均<0.05)。观察组的不良反应发生率低于对照组,差异有统计学意义(10.0% vs 27.5%,P<0.05)。 结论 金水宝胶囊联合环丝氨酸化疗方案可改善耐多药肺结核患者的免疫功能,降低不良反应的发生。
Abstract:Objective To investigate the effect of Jinshuibao capsule combined with chemotherapy regimen containing cycloserine on immune function in patients with multidrug-resistant pulmonary tuberculosis (MDR-TB). Methods Eighty MDR-TB patients treated from January 2015 to January 2016 were divided into observation group and control group (n=40,each).The chemotherapy regimen containing cycloserine,namely 6Am-Z-Lfx-Cs-Pto/18Z-Lfx-Cs-Pto was performed in control group,and Jinshuibao capsule was used in observation group on the basis of 6Am-Z-Lfx-Cs-Pto/18Z-Lfx-Cs-Pto. The curative effect of traditional Chinese medicine(TCM) on the cavity and focus were compared between two groups.The levels of CD3+,CD4+,CD8+,CD4+/CD8+,NK cells were detected before and after treatment,and the adverse reactions were observed during the treatment in two groups. Results There was no significant difference in TCM curative effect,cavity curative effect and focus curative effect between two groups (all P>0.05). After treatment,the CD3+,CD4+,CD4+/CD8+,and NK cells in observation group increased significantly and were higher than those in the control group;CD8+decreased significantly and was lower than that in control group (all P<0.05). The incidence of adverse reactions in observation group was significantly lower than that in control group (10.0% vs 27.5%,P<0.05). ConclusionJinshuibao capsule combined with the chemotherapy regimen containing cycloserine can improve the immune function of patients with MDR-TB and reduce the incidence of adverse reactions.
文章编号:     中图分类号:    文献标志码:B
基金项目:广西壮族自治区卫生和计划委员会科研课题(Z20180498)
引用文本:


Scan with WeChat

Scan with WeChat